Rhythm plans for Initial Public Offering

Rhythm, a biopharmaceutical company developing peptide therapeutics today said that it has filed a registration statement on Form S-1 with the US Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock, reported media.

The number of shares to be offered and the price range for the offering have not yet been determined.

Citigroup and Cowen and Company will act as joint book-running managers for the offering. Canaccord Genuity Inc., Oppenheimer & Co., and Cantor Fitzgerald & Co. will act as co-managers. The offering will be made only by means of a prospectus.